Journal of Clinical Virology 68 (2015) 32–36

Contents lists available at ScienceDirect

Journal of Clinical Virology journal homepage: www.elsevier.com/locate/jcv

Considerable decrease in antibodies against hepatitis B surface antigen following kidney transplantation Valérie Moal a,b,∗ , Anne Motte c , Henri Vacher-Coponat a,d , Catherine Tamalet c , Yvon Berland a,d , Philippe Colson b,c a Centre de Néphrologie et Transplantation Rénale, Assistance Publique - Hôpitaux de Marseille, Centre Hospitalo-Universitaire Conception, 147 boulevard Baille, 13385 Marseille CEDEX 05, France b URMITE, UM63 CNRS 7278 IRD 198, Aix-Marseille Univ., Faculté de Médecine, 27 boulevard Jean Moulin, 13385 Marseille CEDEX 05, France c Fondation IHU Méditerranée Infection, Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Assistance Publique - Hôpitaux de Marseille, Centre Hospitalo-Universitaire Timone 264 rue Saint-Pierre, 13385 Marseille CEDEX 05, France d Aix-Marseille Univ., 13284, Marseille, France

a r t i c l e

i n f o

Article history: Received 7 January 2015 Received in revised form 31 March 2015 Accepted 11 April 2015 Keywords: Hepatitis B virus HBV seroreversion Anti-HBs antibody Kidney transplantation Recipient

a b s t r a c t Background: Immunization against hepatitis B virus (HBV) in kidney transplantation (KT) candidates and recipients is recommended. If anti-HBV surface antigen antibody (anti-HBsAb) titer of 10 IU/L is admitted to be protective, the optimal threshold, at and after KT, is unknown. In addition, the natural evolution of anti-HBsAb titers after KT is not reported. Objectives: To describe rates of protective immunity to HBV at time of KT (baseline) and evolution of anti-HBsAb titers during the following year. Study design: We retrospectively analyzed HBV serology at baseline, 15 days, and 4 and 12 months postKT. No patient received vaccination during the study period, but information about previous vaccination was unavailable. Results: At baseline 80% of 141 recipients had anti-HBsAb titer ≥10 IU/L. Among these 113 patients, 84 had subsequent HBV serologies at day 15 and month 4, and 67 had also serology at month 12. At month 12, 25% of patients had lost protective anti-HBsAb titers (p < 0.001). The duration of protective anti-HBsAb titers was significantly longer when the initial titer was ≥ 100 IU/L versus

Considerable decrease in antibodies against hepatitis B surface antigen following kidney transplantation.

Immunization against hepatitis B virus (HBV) in kidney transplantation (KT) candidates and recipients is recommended. If anti-HBV surface antigen anti...
773KB Sizes 0 Downloads 7 Views